Please assess the completion status of the following clinical trial:

Trial Title: Tolcapone Treatment of Pathological Gambling

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~1. Men and women age 21-75;~2. Meet diagnostic criteria for current pathological gambling based on DSM-IV criteria and confirmed using the clinician-administered Structured Clinical Interview for Pathological Gambling (SCI-PG) (Grant et al., 2004);~3. Gambling behavior within 2 weeks prior to enrollment;~4. Women of child bearing age are required to have a negative result on a beta-human chorionic gonadotropin pregnancy test;~5. Women of childbearing potential utilizing a medically accepted form of contraception defined as double barrier, oral contraceptive, injectable contraceptive, implantable contraceptive devices, and abstinence.~Exclusion Criteria:~1. Infrequent gambling (i.e. less than one time per week) that does not meet DSM-IV criteria for PG;~2. Unstable medical illness or clinically significant abnormalities on laboratory tests, EKG, or physical examination at screen as determined by the investigator;~3. History of elevated liver enzymes (AST/ALT) or other liver abnormalities;~4. History of seizures;~5. Myocardial infarction within 6 months;~6. Current pregnancy or lactation, or inadequate contraception in women of childbearing potential;~7. A need for medication other than tolcapone with possible psychotropic effects or unfavorable interactions as determined by the investigator;~8. Clinically significant suicidality (defined as score 2 or higher on HAM-D item 3);~9. Current co-morbid Axis I disorder determined by the Structured Clinical Interview for DSM-IV (SCID), (First et al., 1995) - except for nicotine dependence;~10. Lifetime history of bipolar disorder type I or II, schizophrenia, or any psychotic disorder determined by SCID;~11. Clinically significant cognitive impairment (defined as score less than 88 on 3MS);~12. Current or recent (past 3 months) DSM-IV substance abuse or dependence;~13. Positive urine drug screen at screening;~14. Initiation of psychotherapy or behavior therapy for pathological gambling within 3 months prior to study baseline;~15. Previous treatment with tolcapone;~16. Treatment with an investigational medication or depot neuroleptics within 3 months;~17. Refusal to sign the tolcapone information sheet.

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 75 Years
- Healthy Volunteers: f

Study Arms:
- Tolcapone (Type: EXPERIMENTAL): Tolcapone 100-300mg/day

Based on this trial design, predict the completion outcome and termination type (if applicable).